MYX
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on commercialising branded and generic drugs in women’s health and dermatology. The company develops and manufactures oral and topical dose forms, including modified-release products and poorly soluble compounds, through its contract development and manufacturing organisation (CDMO) services. Key products include NEXTSTELLIS and IMVEXXY. Mayne Pharma serves markets in Australia and the United States, with a product development and manufacturing facility in Salisbury, Australia. The company partners with clients worldwide for pharmaceutical development, analytical testing, and commercial manufacturing. It maintains a 40-year track record in oral drug delivery systems.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Pharmaceuticals, Biotechnology & Life Sciences Homepage maynepharma.com
Sector Healthcare IR page investors.maynepharma.com
Tags
women's health, dermatology, oral drug delivery, cdmo, branded pharmaceuticals, generic pharmaceuticals, topical formulations, modified-release products, NEXTSTELLIS, IMVEXXY, DistributeRx, Adelaide Apothecary
Press page maynepharma.com/news

Metrics

Valuation  
Market cap A$ 277.61M
Market cap (USD) $ 186.868M
P/E 8.90
PEG —
P/BV 1.24
P/S 0.72
P/OCF 20.02
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 8.2%
ROI 7.2%
ROIC 7.2%
Profit margin 8.1%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -35.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) Yes
Debt/Equity 11.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 2
Quality score 20.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 383.676M 408.095M 388.399M 183.586M 157.147M 400.781M 456.985M 525.208M 530.313M 572.595M 267.28M 60.664M 143.254M 84.071M 52.546M 50.101M 36.713M
Net profit 31.198M -90.071M -211.555M 117.249M -281.286M -17.943M -92.789M -279.203M -133.984M 88.567M 37.355M 10.199M 21.29M -2.843M 6.153M — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MYX enters Scheme Implementation Deed with Gedeon Richter Bull 9 Bear 0 Takeover offer
Investor presentation re Scheme with Gedeon Richter Bull 8 Bear 0 Takeover offer

Prompts

Mayne Pharma Group Limited (ticker MYX), listed in Australia.

ETFs Holding Mayne Pharma Group Limited

ETF Weight in ETF Shares Market value As of
DFIS 0.00% 54,599 $ 126.047K Nov 12, 2026
DFIC 0.00% 52,725 $ 121.72K Nov 12, 2026
DFAX 0.00% 4,930 $ 11.381K Nov 12, 2026
DFAI 0.00% 4,979 $ 11.494K Nov 12, 2026
AVDE 0.00% 42,015 $ 90.396K Nov 16, 2026
AVDV 0.00% 147,610 $ 317.585K Nov 16, 2026
AVSD 0.00% 5,977 $ 12.86K Nov 16, 2026
AVDS 0.00% 5,894 $ 12.681K Nov 16, 2026